Repligen Corporation

RGEN Healthcare Medical Instruments & Supplies

Repligen Corporation’s revenue for fiscal 2025 (year ended December 2025) was $738.3 million, up 16.4% from fiscal 2024.

Revenue
+10.9%
EPS
−351.9%
Free cash flow
−11.5%
Total debt
+3.28%

Quarter to September 2026, against a year earlier

169.01 9.19 −5.16%
Market cap
$10.8B
P/E
0.0×
Fwd P/E
−615×
Dividend yield
—
F-score
6/9
Altman Z
7.49
Beneish M
−2.52
Dividend safety
n/a

Repligen Corporation (RGEN) Operating cash flow

Alert me on Operating cash flow

Repligen Corporation's operating cash flow for fiscal 2025 was $117.4M, down 33.1% from $175.4M in fiscal 2024. Over the twelve months to 30 September 2026 it was $129.9M. Over the past ten years it has ranged from $7.5M (fiscal 2016) to $175.4M (fiscal 2024); the current reading is higher than 73% of that period. Repligen Corporation ranks 20th of 51 Medical Instruments & Supplies companies by operating cash flow.

Operating cash flow, annual

Embed this chart

Annual newest first

Period Operating cash flow Change
FY2025 $117.4M (33.06%)
FY2024 $175.4M 53.97%
FY2023 $113.9M (33.80%)
FY2022 $172.1M 44.59%
FY2021 $119.0M 90.05%
FY2020 $62.6M (6.83%)
FY2019 $67.2M 105.11%
FY2018 $32.8M 87.78%
FY2017 $17.5M 132.03%
FY2016 $7.5M (50.04%)

Quarterly newest first

Period Operating cash flow Change
Sep 2026 $43.1M 31.54%
Jun 2026 $32.8M 15.80%
Mar 2026 $28.3M 10.08%
Dec 2025 $25.7M (46.56%)
43 more quarters

Against its own ten years

Low $7.5M High $175.4M
Ten-year median $67.2M
Current reading's percentile 73

Operating cash flow against peers

What Operating cash flow is

Operating Cash Flow shows how much cash a company’s day-to-day business actually brings in, after paying suppliers, staff and taxes.

Reported line item

The full definition of Operating cash flow →

More on RGEN